Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
This article explores key questions on how Medical Affairs teams manage patient engagement across different-sized companies who have variations in focus, resources, and scale.
This article based on the Oct 3, 2024 Insights FAWG Forum explores the potential for artificial intelligence (AI) to transform Medical Affairs, focusing on medical insights.
The Medical Affairs Professional Society (MAPS) is pleased to share our 2024 Digital, Advanced Analytics and Artificial Intelligence (AI) in Medical Affairs report. This report is based on findings from 32 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors, and reflects broad leadership thinking about the current and future states of Medical Affairs (MA) AI capability and challenges.
Survey design and analysis: Boston Consulting Group led the preparation, execution and analyses of the GenAI survey and moderated the Ambassador GenAI and Advanced Analytics workshop during the MAPS conference on March 24th, 2024.
Survey respondents: 34 representatives from 32 companies responded to our survey.
Participating companies: Thank you to participants from 3M, Abbott, AbbVie, Amgen, Astellas, AstraZeneca, Baxter, Bayer, bioMérieux, BioNTech, BMS, Eisai, Lilly, Gilead, Ipsen, Jazz Pharmaceuticals, Kyowa Kirin, Lundbeck, Mallinckrodt, Merck & Co, Mundipharma, Novartis, Otsuka, Regeneron, Sanofi, Sumitomo Pharma, Takeda, Teva, UCB, Varian, Vertex, and Viatris for your valuable feedback and insights.
The opinions expressed here are those of members of the MAPS Ambassador Alliance and do not necessarily represent the perspectives of their respective companies.
From the Spreadsheet Age to the Age of Generative AI: Where is your organization on the continuum of Insights Management? (And why no one “age” fits the needs of all teams.)
Medical Affairs is in the unique position to drive health equity through three main roles: catalyser, capabilities enhancer, and cross-functional collaborator, emphasizing the need for deliberate strategies and actions to close health gaps and improve outcomes for underserved populations.
In an era when regulatory approvals for new products are rapidly increasing and customers are feeling overwhelmed by new medical information, they are increasingly seeking immediate answers to specific questions. As a result, the need for high-quality, relevant, timely medical information is skyrocketing and the Medical Information function (MI) is rapidly evolving—or trying to—in terms of how the external service operates and its role internally.
A position from MAPS on how Medical Affairs can optimize industry-led and independent Medical Education for maximum value and impact
Through our lens into real-world issues that affect equitable use of industry innovations, Medical Affairs can drive the transformation of industry from a drug-centric perspective to a patient-centric perspective. This article discusses a few of these opportunities.
Omnichannel communication is the strategy of integrating various communication channels, both digital and non-digital, and joining multiple communication touchpoints to provide a seamless, personalized experience, and unified identity across all channels, devices, and touchpoints: the customer (namely HCPs and patients), rather than the product, is at the center.